Here’s our handpicked selection of the best interviews, blog posts, popular articles, and breaking biotech news of the last two weeks: Want a systematic overview of every organization chipping away at human aging right now? Then you’ll love this nearly 800-page report from the Biogerontology Research Foundation. Put it in your queue for bedtime reading….

Here’s our handpicked selection of the best blog posts, popular articles, and breaking biotech news of the last two weeks: Longevity enthusiasts don’t need to feel left out of the mainstream funding frenzy anymore–Y Combinator has put a $1 million bounty on the head of aging, an attractively large figure for up-and-coming startups. Want to…

Many years from now, you’re reclining in one of the many gray-blue armchairs that line the walls of a clinic. Your arm is propped up on a collapsible plastic armrest, and two thin tubes lead from your wrist to the slender white machine next to you, one tube delivering your blood to the machine’s mysterious…

“Aging” isn’t a disease as recognized by the FDA–not yet anyway. But then how will the companies trialing anti-aging drugs ever get regulatory approval? It’s simple: just choose a “primary indication” to test your drug with. Of course, that choice itself is rather difficult when you’re considering a geroprotector. Here’s how investors think about it…

Just getting started around here, or want to introduce someone new to the world of longevity science? This handy primer from Laura Deming (of Longevity Fund) might be just what the doctor ordered. primerLongevity Fund Ring in the new year with retrospectives of 2017 from Fight Aging! and the Life Extension Advocacy Foundation, then start…

Ever hear about an exciting discovery in the biomedical world, then later wonder why it seemingly dropped off the face of the Earth? In fact, it’s par for the course for potential therapeutics to fail before they ever get off the ground, guided unwittingly by their enthusiastic champions straight into a boneyard strewn with the…

We want you! Reason over at Fight Aging! lists nine promising approaches to rejuvenation therapy that he’d like to see in the very near future: assessment of senolytics, medical tourism, immune rejuvenation, glucosepane cross-link breaking, amyloid clearance, lysosome cleanup, telomere-centric blockades of cancer, cell therapies, and improved gene therapy. If this describes your work, consider

No one should have to read during the holidays. That’s why we made you a video! I spoke to our own James Peyer about how he got started in the longevity world, the unique challenges of bringing new anti-aging therapeutics to the public, and how his role as an investor allows him to help projects

Last Wednesday I attended the Buck Institute’s workshop on AI and Longevity, where speakers from several different organizations discussed how they were using machine learning to advance different aspects of medical discovery. Uses for AI in aging include creating new drugs, finding new uses for existing drugs, and discovering new biomarkers–all of which are important…

“At what age would you like to get Alzheimer’s?” This was the question posed by venture capitalist, former stem cell biologist and Geroscience co-founder James Peyer at TEDxStuttgart last week. Peyer became a devotee and champion of the anti-aging movement early in his life, and over his career he’s watched the field mature from a collection…

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD